Skip to main content
. 2021 Aug 10;10(4):1933–1947. doi: 10.1007/s40121-021-00515-6

Fig. 1.

Fig. 1

BLAZE-1 phase 2/3 study design to evaluate the efficacy of bamlanivimab alone and together with etesevimab in ambulatory participants with mild to moderate COVID-19 illness. Doses of bamlanivimab and etesevimab presented in brackets. N number of patients in cohort